Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10448155 | 0.98 | ALDH1A1 (0.50) | ALDH1A1CES1CES2DGKATP53 | |
| SCHEMBL1238292 | 0.93 | DGKA (0.56) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL28412264 | 0.93 | ALDH1A1 (0.56) | ALDH1A1CES1CES2DGKATP53 | |
| SCHEMBL2235744 | 0.91 | DGKA (0.59) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL1698285 | 0.91 | DGKA (0.59) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL8603407 | 0.91 | DGKA (0.54) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL4631670 | 0.91 | DGKA (0.59) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL20482068 | 0.91 | DGKA (0.54) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL20482050 | 0.91 | DGKA (0.54) | ALDH1A1CES1CES2DGKALMNA | |
| SCHEMBL22126637 | 0.91 | DGKA (0.59) | ALDH1A1CES1CES2DGKALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002506-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2025-01-02 | — | — | US | claimed |
| CN-114058279-B | Curved screen protective film, preparation method and application thereof | 安徽屹珹新材料科技有限公司 | 2023-12-08 | — | — | CN | claimed |
| US-11723873-B2 | Oral dosage form of ticagrelor and preparation method thereof | Elite Pharmaceutical Solution Inc. (US) | 2023-08-15 | — | — | US | claimed |
| WO-2023084329-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RK PHARMA INC. (US) | 2023-05-19 | — | — | WO | claimed |
| CN-115715184-A | Ticagrelor oral dosage form and preparation method thereof | 赛乐医药科技有限公司 | 2023-02-24 | — | — | CN | claimed |
| US-20220409545-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | Elite Pharmaceutical Solution Inc. (US) | 2022-12-29 | — | — | US | claimed |
| WO-2022271167-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | Elite Pharmaceutical Solution Inc. (US) | 2022-12-29 | — | — | WO | claimed |
| CN-114058279-A | Curved screen protective film, preparation method and application thereof | 安徽屹珹新材料科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-105152903-B | Preparation method of aliphatic dicarboxylic acid | 中国科学院宁波材料技术与工程研究所 | 2021-03-16 | — | — | CN | claimed |
| CN-107936186-B | 3D printing wire and preparation method thereof | 中国石油化工股份有限公司 | 2020-06-09 | — | — | CN | claimed |
| EP-0626986-B1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN | EASTMAN CHEM CO (US) | 1996-03-20 | — | — | EP | claimed |
| EP-0626986-A1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN. | EASTMAN CHEM CO (US) | 1994-12-07 | — | — | EP | claimed |
| US-5334638-A | Aqueous dispersion useful in coatings containing hydrolyzed cellulose ester and acyrlic resin | EASTMAN CHEMICAL COMPANY (US) | 1994-08-02 | — | — | US | claimed |
| WO-1993014168-A1 | AQUEOUS DISPERSION USEFUL IN COATINGS CONTAINING HYDROLYZED CELLULOSE ESTER AND ACRYLIC RESIN | EASTMAN KODAK COMPANY (US) | 1993-07-22 | — | — | WO | claimed |
| EP-0227093-B1 | CELLULOSIC BINDER FOR DYE-DONOR ELEMENT USED IN THERMAL DYE TRANSFER | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-11-07 | — | — | EP | claimed |
| US-4700207-A | CELLULOSE TRIACETATE OR CELLULOSE MIXED ESTER | EASTMAN KODAK COMPANY (US) | 1987-10-13 | — | — | US | claimed |
| EP-0227093-A2 | Cellulosic binder for dye-donor element used in thermal dye transfer | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1987-07-01 | — | — | EP | claimed |
| US-4111203-A | OSMOTIC SYSTEM WITH MEANS FOR IMPROVING DELIVERY KINETICS OF SYSTEM | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-4111202-A | OSMOTIC SYSTEM FOR THE CONTROLLED AND DELIVERY OF AGENT OVER TIME | ALZA CORPORATION (US) | 1978-09-05 | — | — | US | claimed |
| US-4058122-A | Osmotic system with laminated wall formed of different materials | ALZA CORPORATION (US) | 1977-11-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002506-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LURBINECTEDIN AND ITS MORPHS THEREOF | RXFP1, REN, CIAPIN1 | ALDH1A1 1940/4885CES1 969/4885CES2 4211/4885 |
| US-11723873-B2 | Oral dosage form of ticagrelor and preparation method thereof | TMEM165, ABCB11, ABCG2 | ALDH1A1 1791/4885CES1 2637/4885CES2 2033/4885 |
| US-20220409545-A1 | ORAL DOSAGE FORM OF TICAGRELOR AND PREPARATION METHOD THEREOF | TMEM165, ABCB11, ABCG2 | ALDH1A1 1791/4885CES1 2637/4885CES2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.